Synonyms: AG-221 | CC-90007 | Idhifa®
enasidenib is an approved drug (FDA (2017))
Compound class:
Synthetic organic
Comment: Enasidenib (AG-221) is an orally available inhibitor of isocitrate dehygrogenase 2 (IDH2), that is approved as an antineoplastic agent. This compound is example 409 in patent US20130190287 A1 [1].
|
|
References |
1. Cianchetta G, Delabarre B, Popovici-Muller J, Salituro FG, Saunders JO, Travins J, Yan S, Guo T, Zhang L. (2013)
Therapeutically active compounds and their methods of use. Patent number: US20130190287 A1. Assignee: Agios Pharmaceuticals, Inc.. Priority date: 06/01/2012. Publication date: 25/07/2013. |
2. Kim ES. (2017)
Enasidenib: First Global Approval. Drugs, 77 (15): 1705-1711. [PMID:28879540] |